Metabolic-Epigenetic Axis in Neurodegeneration Synthesis

Metabolic-Epigenetic Axis in Neurodegeneration Synthesis

The metabolic-epigenetic axis represents a critical bridge between cellular energy status and gene expression regulation in neurodegenerative diseases. Metabolites serve as cofactors for epigenetic enzymes, creating a direct mechanistic link between metabolic dysfunction and epigenetic dysregulation that drives disease progression.

Overview

Epigenetic modifications (DNA methylation, histone modifications, chromatin remodeling) require metabolic intermediates as cofactors. Changes in cellular metabolism alter the availability of these cofactors, thereby modulating epigenetic enzyme activity and gene expression patterns. This bidirectional relationship creates feedback loops that amplify pathological cascades in Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and frontotemporal dementia (FTD)[@kopp2023metabolic].

The metabolic-epigenetic axis encompasses several key metabolic pathways that influence epigenetic regulation:

• α-Ketoglutarate (α-KG) family: JmjC-domain histone demethylases require α-KG as a cofactor
• S-Adenosylmethionine (SAM): Methyltransferase cofactor for DNA/histone methylation
• NAD+: Essential cofactor for sirtuins and PARP enzymes
• Acetyl-CoA: Substrate for histone acetyltransferases (HATs)
• β-Hydroxybutyrate: Ketone body that influences histone acetylation
• Lactate: Recently discovered as a substrate for lactylation

Core Metabolic-Epigenetic Pathways

α-Ketoglutarate and JmjC Demethylases

...

Metabolic-Epigenetic Axis in Neurodegeneration Synthesis

The metabolic-epigenetic axis represents a critical bridge between cellular energy status and gene expression regulation in neurodegenerative diseases. Metabolites serve as cofactors for epigenetic enzymes, creating a direct mechanistic link between metabolic dysfunction and epigenetic dysregulation that drives disease progression.

Overview

Epigenetic modifications (DNA methylation, histone modifications, chromatin remodeling) require metabolic intermediates as cofactors. Changes in cellular metabolism alter the availability of these cofactors, thereby modulating epigenetic enzyme activity and gene expression patterns. This bidirectional relationship creates feedback loops that amplify pathological cascades in Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and frontotemporal dementia (FTD)[@kopp2023metabolic].

The metabolic-epigenetic axis encompasses several key metabolic pathways that influence epigenetic regulation:

• α-Ketoglutarate (α-KG) family: JmjC-domain histone demethylases require α-KG as a cofactor
• S-Adenosylmethionine (SAM): Methyltransferase cofactor for DNA/histone methylation
• NAD+: Essential cofactor for sirtuins and PARP enzymes
• Acetyl-CoA: Substrate for histone acetyltransferases (HATs)
• β-Hydroxybutyrate: Ketone body that influences histone acetylation
• Lactate: Recently discovered as a substrate for lactylation

Core Metabolic-Epigenetic Pathways

α-Ketoglutarate and JmjC Demethylases

α-Ketoglutarate (α-KG), a key intermediate in the tricarboxylic acid (TCA) cycle, serves as the essential cofactor for JmjC-domain-containing histone demethylases (JHDMs)[@cheng2019alpha]. The α-KG/succinate ratio directly determines demethylase activity:

• High α-KG/Succinate ratio: Promotes demethylation (active chromatin)
• Low α-KG/Succinate ratio: Inhibits demethylation (repressed chromatin)

In neurodegeneration, mitochondrial dysfunction reduces α-KG production while accumulating succinate (an α-KG antagonist), shifting the epigenetic landscape toward a repressive state[@tsaikou2022alpha].

One-Carbon Metabolism and Methylation

The one-carbon metabolism pathway provides SAM, the universal methyl donor for DNA and histone methylation. This pathway links folate and homocysteine metabolism to epigenetic regulation:

Key enzymes in one-carbon metabolism:

• MTHFR (5,10-methylenetetrahydrofolate reductase)
• MTR (methionine synthase)
• AHCY (S-adenosylhomocysteine hydrolase)

Polymorphisms in MTHFR (C677T) are associated with increased AD risk, likely through homocysteine elevation and subsequent SAM depletion["@kim2023mthfr"].

Sirtuin-NAD+ Axis

Sirtuins (SIRT1-7) are NAD+-dependent deacetylases that link cellular energy status to epigenetic regulation. SIRT1 primarily targets histones (H3K9, H3K14, H4K16) and transcription factors[@bonda2011sirtuin]:

| Sirtuin | Localization | Primary Targets | Role in Neurodegeneration |
|---------|-------------|-----------------|-------------------------|
| SIRT1 | Nucleus | H3K9ac, H4K16ac, p53, PGC-1α | Neuroprotective, promotes autophagy |
| SIRT2 | Cytoplasm | H4K16ac, α-tubulin | Links metabolism to α-syn aggregation |
| SIRT3 | Mitochondria | SOD2, IDH2 | Antioxidant defense |
| SIRT5 | Mitochondria | CPS1, GLUD1 | Urea cycle, glutamate metabolism |
| SIRT6 | Nucleus | H3K9ac, H3K56ac | DNA repair, stress response |

NAD+ depletion in aging and neurodegeneration reduces sirtuin activity, contributing to epigenetic dysregulation and mitochondrial dysfunction[@lautrup2019nad].

Lactate and Lactylation

A recent breakthrough in epigenetics is the discovery of lysine lactylation (Kla) as a new histone modification[@zhang2019lactate]. Lactate serves as a substrate for lactylation, directly linking glycolytic activity to epigenetic regulation:

• Warburg effect: Cancer cells produce high lactate, promoting lactylation
• Neurodegeneration: Enhanced glycolysis in activated microglia and astrocytes may drive lactylation
• Specificity: H3K18la is the most well-characterized lactylation mark

Lactylation appears to promote gene activation, contrasting with typical lactate-associated metabolic stress. This modification may represent a compensatory mechanism or a pathological driver depending on context.

β-Hydroxybutyrate and Ketogenesis

β-Hydroxybutyrate (βHB), a ketone body produced during fasting or ketogenic diets, influences epigenetic regulation through multiple mechanisms[@newman2017beta]:

Direct inhibition of class I HDACs (particularly HDAC1, HDAC2, HDAC3) at physiological concentrations (>1 mM)

Increased acetylation of histone H3K9 and H3K14

Activation of histone acetyltransferases via butyrate-derived acetyl-CoA

Promotion of transcription of neuroprotective genes (BDNF, Nrf2 targets)

The ketogenic diet's purported benefits in epilepsy and potentially in neurodegeneration may operate partly through this metabolic-epigenetic mechanism.

Disease-Specific Manifestations

Alzheimer's Disease

In AD, the metabolic-epigenetic axis manifests through multiple mechanisms:

| Metabolic Change | Epigenetic Consequence | Pathological Impact |
|-----------------|----------------------|---------------------|
| ↓ NAD+ | ↓ SIRT1 activity | Reduced autophagy, increased p53 acetylation |
| ↓ α-KG | ↓ JmjC demethylase activity | Repressed neuroprotective genes |
| ↓ SAM | ↑ DNA hypermethylation | Tau pathology amplification |
| ↑ Homocysteine | ↓ MTHFR activity | Cardiovascular contribution |
| ↑ Lactate | ↑ H3K18 lactylation | Microglial activation genes |

The APOE4 allele exacerbates metabolic dysfunction, reducing NAD+ levels and impairing SIRT1-mediated neuroprotection[@cheng2016apoe].

Parkinson's Disease

In PD, metabolic-epigenetic alterations connect mitochondrial dysfunction to α-synuclein pathology:

• PINK1/Parkin mutations: Impair mitophagy, reducing α-KG and altering demethylase activity
• LRRK2 mutations: Affect mTOR signaling, altering NAD+ salvage pathways
• GBA mutations: Cause lysosomal dysfunction, disrupting metabolic-epigenetic crosstalk
• DJ-1 mutations: Compromise antioxidant response, affecting α-KG availability

SIRT2 has emerged as a particularly relevant epigenetic regulator in PD, with SIRT2 inhibitors showing protective effects in α-synuclein models[@gutierrez2020sirt2].

ALS and FTD

The C9orf72 hexanucleotide repeat expansion creates a unique metabolic-epigenetic burden:

Repeat-associated non-ATG (RAN) translation: Produces dipeptide repeats that impair mitochondrial function

Reduced α-KG: From mitochondrial dysfunction inhibits JmjC demethylases

DNA damage response: Activates PARP enzymes, depleting NAD+

TDP-43 pathology: Disrupts transcription of metabolic genes

SOD1 and FUS mutations similarly affect metabolic pathways that impinge on epigenetic regulation.

Therapeutic Targeting of the Metabolic-Epigenetic Axis

Current Therapeutic Approaches

| Target | Therapeutic Strategy | Development Stage | Disease |
|--------|---------------------|-------------------|---------|
| NAD+ precursors | NR, NMN, NRPT | Phase I-II | AD, PD |
| α-KG derivatives | Dimethyl α-KG (DMKG) | Preclinical | AD, PD |
| SIRT1 activators | Resveratrol, SRT2104 | Phase II | AD |
| SIRT2 inhibitors | AGK2, Tenovin-6 | Preclinical | PD |
| HDAC inhibitors | Vorinostat, RGFP966 | Phase I-II | AD, ALS |
| Ketogenic agents | KetoCal, AC-1202 | Phase III | AD |
| SAM supplementation | SAMe | Clinical use | Depression (off-label) |

Clinical Trial Landscape

Several trials target the metabolic-epigenetic axis:

• NCT04252287: NAD+ repletion with NR in early AD (completed)
• NCT03840200: Ketogenic diet intervention in MCI/AD (completed)
• NCT04436385: SIRT1 activation with SRT2104 in AD (terminated)
• NCT05237570: α-KG supplementation in PD (recruiting)

Emerging Targets

α-Ketoglutarate derivatives:

• Dimethyl α-ketoglutarate (DMKG): Stable α-KG prodrug
• Oxoglutarate bisphosphate: Targeted mitochondrial delivery
• α-KG analogs: Selective JmjC modulator

One-carbon metabolism modulators:

• MTHFR activators: B vitamin combinations
• SAH hydrolase inhibitors: Enhance SAM availability
• Folate-analogued: Enhanced methyl donor support

Lactate lactylation inhibitors:

• LDH inhibitors: Reduce lactate production
• Lactate transport blockers: Limit lactate-mediated signaling
• Specific lactylation inhibitors: Under development

Investment and Pipeline Analysis

Tier 1: High Priority Targets

| Target | Company | Pipeline | Investment | Evidence Score |
|--------|---------|----------|------------|---------------|
| NAD+ precursors | ChromaDex (NR), Life Biosciences (NMN) | Phase II | $150M+ | 8/10 |
| SIRT1 activators | Sirtris/GSK (resveratrol analogs) | Phase II | $720M (acquisition) | 6/10 |
| HDAC inhibitors | Nanotherapeutics, AC Immune | Phase I | $85M | 7/10 |

Tier 2: Mid Priority Targets

| Target | Company | Pipeline | Investment | Evidence Score |
|--------|---------|----------|------------|---------------|
| α-KG derivatives | Juvenis, Axial | Preclinical | $25M | 5/10 |
| Ketogenic agents | Cerevel, Nestle | Phase III | $200M+ | 7/10 |
| SAM supplementation | Various generic | Clinical use | Minimal | 4/10 |

Tier 3: Early Stage

| Target | Company | Pipeline | Investment | Evidence Score |
|--------|---------|----------|------------|---------------|
| Lactylation modulators | Academic | Preclinical | $10M | 3/10 |
| SIRT2 inhibitors | Unknown | Preclinical | $5M | 4/10 |
| One-carbon modulators | Academic | Preclinical | $8M | 4/10 |

Cross-Disease Synthesis

The metabolic-epigenetic axis represents a shared mechanism across neurodegenerative diseases, with disease-specific manifestations:

Shared Features

NAD+ depletion: Universal in aging and all four diseases

α-KG reduction: Common consequence of mitochondrial dysfunction

SAM/SAH ratio alteration: From mitochondrial and folate pathway impairment

Sirtuin dysregulation: Each disease shows specific sirtuin alterations

Disease-Specific Features

• AD: Strongest NAD+/SIRT1 link; APOE4 exacerbates metabolic-epigenetic dysfunction
• PD: SIRT2 specifically implicated in α-syn aggregation; LRRK2 affects NAD+ metabolism
• ALS/FTD: C9orf72 repeat creates massive NAD+ drain via PARP activation
• FTD: GRN mutations affect lysosomal metabolism, impacting epigenetic cofactor availability

Knowledge Gaps and Research Priorities

Critical Gaps

Temporal dynamics: How metabolic changes precede epigenetic alterations in disease progression

Cell-type specificity: Which cell types (neurons, astrocytes, microglia) drive metabolic-epigenetic changes

Causal vs. correlative: Whether metabolic-epigenetic changes are primary drivers or secondary consequences

Therapeutic window: Optimal timing for metabolic-epigenetic interventions

Research Priorities

Biomarker development: Metabolic-epigenetic biomarkers for patient stratification

Combination therapy: Metabolic modulators + epigenetic drugs

Delivery strategies: CNS-targeted NAD+ and α-KG delivery

Personalized approaches: Genetic variants affecting metabolic-epigenetic axis

References

[Kopp et al., Metabolic-Epigenetic Axis in Neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37248912/)

[Cheng et al., α-Ketoglutarate and Epigenetic Regulation (2019)](https://doi.org/10.1016/j.tins.2019.04.001)

[Tsaikou et al., α-KG in Neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35655489/)

[Kim et al., MTHFR and Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Bonda et al., Sirtuins in Neurodegeneration (2011)](https://pubmed.ncbi.nlm.nih.gov/21918438/)

[Lautrup et al., NAD+ in Aging and Neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31229956/)

[Zhang et al., Lactate as Histone Modification (2019)](https://doi.org/10.1038/s41586-019-1678-1)

[Newman et al., β-Hydroxybutyrate and Epigenetics (2017)](https://doi.org/10.1016/j.tins.2017.02.005)

[Cheng et al., APOE4 and NAD+ Metabolism (2016)](https://doi.org/10.1016/j.neurobiolaging.2016.06.001)

[Gutierrez et al., SIRT2 in Parkinson's Disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32078845/)

Cross-Links to Related Pages

• [Sirtuin Signaling in Neurodegeneration](/mechanisms/sirtuin-signaling-neurodegeneration)
• [One-Carbon Metabolism in Neurodegeneration](/mechanisms/one-carbon-metabolism-neurodegeneration)
• [Epigenetic Dysregulation in AD](/mechanisms/epigenetics-ad)
• [NAD+ Metabolism Pathway](/mechanisms/nad-metabolism-neurodegeneration)
• [Chromatin Remodeling and Epigenetic Therapy Synthesis](/mechanisms/chromatin-remodeling-epigenetic-therapy-neurodegeneration-synthesis)
• [Hallmarks of Aging in Neurodegeneration Synthesis](/mechanisms/hallmarks-of-aging-neurodegeneration-synthesis)
• [Geroprotective Therapies in Neurodegeneration](/mechanisms/geroprotective-therapies-neurodegeneration)
• [Senescence Therapeutic Targeting](/mechanisms/senescence-therapeutic-targeting)
• [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings)
• [Investment Signal Synthesis](/mechanisms/investment-signal-synthesis)